Medtronic ($MDT) has completed its MiniMed ($MMED) split-off, and the odd-lot preference held up under heavy demand. Final results announced October 14 show that qualifying holders of fewer than 100 MDT shares who tendered their entire positions had all their shares accepted, while ordinary tenders received an 18.289133% proration factor. Yet our hypothetical 99-share trade, marked at MMED’s October 15 closing price, is down 7.4% from its September reference cost.
Get Inelegant Investor by email Odd lots, special situations, market mechanics and other opportunities most investors miss.
We established the 99-share paper position on September 24, using the prior day’s $89.30 MDT closing price as our entry reference. The hypothetical cost was $8,840.70, and the intended action was to tender all 99 shares by the deadline. No actual trade or liquidation is being represented here: the record is a paper calculation using published exchange terms and subsequent market prices.
Odd-lot holders avoided the 18.3% proration
Medtronic accepted 55,032,401 MDT shares in exchange for its remaining 252,813,348 MiniMed shares. The company received valid tenders of 297,521,390 MDT shares, including 757,890 shares from eligible odd-lot holders, according to its final filing. The broader offer was approximately 5.4 times subscribed; Medtronic confirmed October 15 that it no longer owns any MiniMed equity.
For a properly tendered 99-share position that met the beneficial-ownership and all-shares requirements, the exemption meant acceptance of all 99 MDT shares. At the final 4.5939 MMED shares per MDT share, that’s an economic entitlement of 454.7961 MMED shares. The transfer agent credits 454 whole shares and pays cash in lieu of the 0.7961 fractional share after selling aggregated fractional interests; the final cash payment is not yet known.
Our 99-share paper trade: down 7.4% at the October 15 close
MMED closed October 14 at $16.81, putting the paper entitlement at $7,645.12, or 13.52% below the reference purchase price. The stock then rebounded to $18.00 on October 15, lifting the marked value to $8,186.33. That leaves an indicative loss of $654.37, or 7.40%, before brokerage fees, tax effects and any difference between the assumed fractional-share value and the cash eventually distributed.
| Tracked paper position | Amount |
|---|---|
| MDT reference purchase: 99 × $89.30, September 23 | $8,840.70 |
| Final exchange ratio | 4.5939 MMED per MDT |
| Economic MMED entitlement: 99 × 4.5939 | 454.7961 shares |
| MMED closing price, October 14 | $16.81 |
| Paper value at October 14 close | $7,645.12 |
| Paper return at October 14 close | -13.52% |
| MMED closing price, October 15 | $18.00 |
| Paper value at October 15 close | $8,186.33 |
| Paper loss at October 15 close | -$654.37 |
| Paper return at October 15 close | -7.40% |
This mark values all 454.7961 MMED shares at the specified closing quote for comparison, even though actual settlement involves 454 whole shares and cash for a fraction. It is not a realized trading result, and a participant who bought MDT at another price or sold MMED on another date would have a different outcome. The October 15 recovery also shows why a postmortem needs a dated price mark rather than a claim that a tender created a fixed loss.
How an attractive exchange discount became a loss
The exchange was marketed around a 7% discount to relative market values, equivalent to roughly $107.53 of MMED for every $100 of MDT accepted when the upper exchange-ratio limit did not apply. But the final calculation hit the cap of 4.5939 MMED shares per MDT share. At our September 23 reference price of $20.54 for MMED, that capped ratio implied $9,341.51 of MiniMed shares for a 99-share tender, or a paper gross gain of $500.81 before market movement.
Instead, MMED fell from $20.54 on September 23 to $16.81 on October 14 before rebounding to $18.00 on October 15. On that later date, the original 454.7961-share entitlement was worth approximately $1,155 less than the $9,341.51 suggested by the initial price snapshot. The exemption solved the allocation problem in an oversubscribed offer; it offered no protection from changes in MMED’s market price after the exchange ratio was fixed.
There is also a useful opportunity-cost comparison. MDT closed October 15 at $95.45, so retaining 99 MDT shares would have represented $9,449.55 at that closing price, about $1,263.22 more than the marked MMED entitlement. This is a hypothetical hold-versus-tender comparison, excluding dividends, transaction costs and tax consequences; it does not establish what a real investor could have sold either position for after settlement.
Settlement is still the unfinished part
MiniMed’s October 15 completion announcement says whole shares will be credited in book-entry form, with fractional-share checks delivered after the exchange agent aggregates and sells the fractions. For our hypothetical odd lot, the unknown fractional cash proceeds relate to 0.7961 MMED share. Any later market sale of the 454 whole shares would also change the realized outcome, so the paper position remains open for tracking rather than being presented as closed.
The company described the exchange as intended to be generally tax-free to participating U.S. shareholders, apart from cash paid for fractional shares. The tax basis and holding period rules for an exchange of this kind can differ from a straightforward sale, so the negative paper return should not be treated as an automatically deductible capital loss. The case demonstrates the narrow value of odd-lot priority: it assured acceptance for qualifying tenders in this oversubscribed transaction, but it did not eliminate the much larger price risk in a nearly $9,000 position.